AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3035166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 231
Study 29797912 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraplegic triple needling combined with rehabilitation training
Number of subjects: 50
Study 29797912 — intervention group
Group type: COMPARATOR
Intervention: Conventional needling combined with rehabilitation training
Number of subjects: 50
Study 26321112 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Bundle ACL Reconstruction
Number of subjects: 64
Study 26321112 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-Bundle ACL Reconstruction
Number of subjects: 64
Study 26321112 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 64
Study 25429853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 222
Study 25429853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU
Number of subjects: 222
Study 25429853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 25429853 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH resolution
Number of subjects: 222
Study 23419093 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratinocyte growth factor (palifermin, 60 μg/kg)
Number of subjects: 0
Study 23419093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 0
Study 20544030 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-assisted treatment
Number of subjects: 141
Study 20544030 — intervention group
Group type: EXPERIMENTAL
Intervention: Technician-assisted treatment
Number of subjects: 141
Study 20544030 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 141
Study 19301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sexual initiation among boys (34.9%)
Number of subjects: 1514
Study 19301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sexual initiation among girls (20.6%)
Number of subjects: 1514
Study 19301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for boys
Number of subjects: 1514
Study 19301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for girls
Number of subjects: 1514
Study 19301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sexual partners among boys (37.3%)
Number of subjects: 1514
Study 19301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sexual partners among girls (12.9%)
Number of subjects: 1514
Study 16631431 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution (n=8)
Number of subjects: 32
Study 16631431 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-g essential amino acid mixture (n=8)
Number of subjects: 32
Study 16631431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined carbohydrate and essential amino acid supplement (n=8)
Number of subjects: 32
Study 16631431 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (n=8)
Number of subjects: 32
Study 12812357 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine-artesunate
Number of subjects: 0
Study 12812357 — intervention group
Group type: COMPARATOR
Intervention: mefloquine-primaquine
Number of subjects: 0
Study 11553245 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming
Number of subjects: 59
Study 11553245 — intervention group
Group type: COMPARATOR
Intervention: Conventional blankets without active warming (Control)
Number of subjects: 59
Study 9553683 — intervention group
Group type: EXPERIMENTAL
Intervention: Controfilina-200 (test preparation)
Number of subjects: 12
Study 9553683 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 12
Study 7998664 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 106
Study 7998664 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 106
Study 7998664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 3189898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 33
Study 3189898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 1 mg
Number of subjects: 33
Study 3189898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 2.5 mg
Number of subjects: 33
Study 3189898 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 33
Study 30027669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease cohort with SNP genotyping
Number of subjects: 2795
Study 30027669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease cohort
Number of subjects: 2795
Study 26336919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium bicarbonate (3 ml/kg/h for 1 h; n = 43)
Number of subjects: 130
Study 26336919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium citrate (75 ml/10 kg divided into 4 doses; n = 43)
Number of subjects: 130
Study 26336919 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific hydration (n = 44)
Number of subjects: 130
Study 26336919 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 130
Study 24252587 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief-Help (cognitive behavioural treatment) combined with five sessions of parental counselling
Number of subjects: 160
Study 24252587 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling combined with five sessions of parental counselling
Number of subjects: 160
Study 21262791 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterlow screening tool (n=410)
Number of subjects: 1231
Study 21262791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramstadius screening tool (n=411)
Number of subjects: 1231
Study 21262791 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgement (n=410)
Number of subjects: 1231
Study 18768432 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot octreotide (100 microg subcutaneously on day 1, followed by 20 mg intramuscularly on days 2 and 29)
Number of subjects: 125
Study 18768432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 18768432 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot octreotide
Number of subjects: 125
Study 17137546 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (oral trimethoprim-sulfamethoxazole, amoxicillin, or doxycycline)
Number of subjects: 917
Study 17137546 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 917
Study 17137546 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (7 days)
Number of subjects: 917
Study 12703393 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused videotape instruction in the clinic (n = 106)
Number of subjects: 215
Study 12703393 — intervention group
Group type: COMPARATOR
Intervention: Control (no instruction in the clinic waiting area) (n = 109)
Number of subjects: 215
Study 10720524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis toxoid vaccination
Number of subjects: 813
Study 9370552 — intervention group
Group type: EXPERIMENTAL
Intervention: ProHance administered at doses ranging from 0.1 mmol/kg to 0.3 mmol/kg
Number of subjects: 2656
Study 9370552 — intervention group
Group type: EXPERIMENTAL
Intervention: ProHance at a higher dose level of 0.3 mmol/kg
Number of subjects: 2656
Study 1383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms) administered intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP
Number of subjects: 245
Study 1383099 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 245
Study 1383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 245
Study 1383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions
Number of subjects: 245
Study 31828089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity motor control exercises added to the standard rehabilitation program
Number of subjects: 32
Study 31828089 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program
Number of subjects: 32
Study 29523800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid neurogranin
Number of subjects: 0
Study 29523800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid TREM2
Number of subjects: 0
Study 29523800 — intervention group
Group type: COMPARATOR
Intervention: Age adjustment for TREM2
Number of subjects: 0
Study 26209090 — intervention group
Group type: EXPERIMENTAL
Intervention: GC rs2282679 genotype
Number of subjects: 702
Study 25260889 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcaftadine 0.25%
Number of subjects: 284
Study 25260889 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2%
Number of subjects: 284
Study 22961907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry diet (400 g fresh bilberries daily)
Number of subjects: 27
Study 22961907 — intervention group
Group type: COMPARATOR
Intervention: Control diet (habitual diet)
Number of subjects: 27
Study 30178742 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose plus metformin
Number of subjects: 30
Study 30178742 — intervention group
Group type: COMPARATOR
Intervention: Individual voglibose and metformin tablets
Number of subjects: 30
Study 30178742 — intervention group
Group type: COMPARATOR
Intervention: Voglibose alone
Number of subjects: 30
Study 30178742 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual voglibose and metformin tablets and FDC
Number of subjects: 30
Study 17559845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance during embryo transfer
Number of subjects: 5968
Study 17559845 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch method
Number of subjects: 5968
Study 16549926 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency sinus excision (RSE)
Number of subjects: 44
Study 16549926 — intervention group
Group type: COMPARATOR
Intervention: Wide excision and healing by open granulation procedure (WEG)
Number of subjects: 44
Study 12399264 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study 12399264 — intervention group
Group type: COMPARATOR
Intervention: Other dietary oils (palm oil, safflower oil, fish and safflower oil mixture)
Number of subjects: 0
Study 9973874 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulated balance arm
Number of subjects: 4
Study 9973874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic hoist
Number of subjects: 4
Study 9973874 — intervention group
Group type: COMPARATOR
Intervention: Manual lifting
Number of subjects: 4
Study 8643018 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study 8643018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosed intravenous immunoglobulins (0.4 g/kg/daily for five days)
Number of subjects: 0
Study 8643018 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (500 mg methylprednisolone daily for five days)
Number of subjects: 0
Study 8643018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with high dose methylprednisolone and immunoglobulins
Number of subjects: 0
Study 8643018 — intervention group
Group type: COMPARATOR
Intervention: General medical care and supportive therapy in the intensive care unit
Number of subjects: 0
Study 2197003 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 2197003 — intervention group
Group type: COMPARATOR
Intervention: Diazemuls (diazepam in oil emulsion)
Number of subjects: 60
Study 2197003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received fentanyl 0.5 micrograms.kg‐1 IV
Number of subjects: 60
Study 7022706 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose carbenicillin prophylaxis preoperatively
Number of subjects: 50
Study 7022706 — intervention group
Group type: COMPARATOR
Intervention: T-tube suction drainage postoperatively
Number of subjects: 50
Study 31794130 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 131
Study 31794130 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 131
Study 31794130 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 131
Study 31794130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca+ channel blocker (verapamil or nicardipine)
Number of subjects: 131
Study 27729394 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 86
Study 27729394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 86
Study 25885818 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 0
Study 25885818 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 0
Study 23989522 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg/day prednisolone (group A, n = 35)
Number of subjects: 69
Study 23989522 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg/day prednisolone (group B, n = 34)
Number of subjects: 69
Study 21052886 — intervention group
Group type: COMPARATOR
Intervention: Group counseling (n=21)
Number of subjects: 67
Study 21052886 — intervention group
Group type: COMPARATOR
Intervention: Individual consultation (n=22)
Number of subjects: 67
Study 21052886 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=24)
Number of subjects: 67
Study 19996400 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled oxygen at 100%, 12 L/min, delivered by face mask for 15 minutes.
Number of subjects: 109
Study 19996400 — intervention group
Group type: COMPARATOR
Intervention: High-flow air placebo delivered alternately for 4 attacks.
Number of subjects: 109
Study 17471214 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA use
Number of subjects: 12
Study 15588478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size and marker set
Number of subjects: 0
Study 15588478 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker set
Number of subjects: 0
Study 11283037 — intervention group
Group type: EXPERIMENTAL
Intervention: ViroSeq HIV-1 Genotyping System
Number of subjects: 196
Study 9399720 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic testing with highly reproducible arrhythmias
Number of subjects: 473
Study 9399720 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiologic testing with less reproducible arrhythmias
Number of subjects: 473
Study 7955184 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 151
Study 7955184 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 151
Study 2821808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times a day)
Number of subjects: 50
Study 2821808 — intervention group
Group type: COMPARATOR
Intervention: Alginate/antacid compound (5 g four times a day)
Number of subjects: 50
Study 30668179 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% Potassium hydroxide (KOH) gel applied once daily up to clearing (maximum 30 days)
Number of subjects: 0
Study 30668179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30668179 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% Potassium hydroxide (KOH) gel
Number of subjects: 0
Study 27350144 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection in the medial orbicularis muscle of the lower eyelid
Number of subjects: 20
Study 27350144 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Number of subjects: 20
Study 27350144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham group)
Number of subjects: 20
Study 26153128 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan 0.75 mg/d
Number of subjects: 211
Study 26153128 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan 1.25 mg/d
Number of subjects: 211
Study 26153128 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 211
Study 26153128 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan (both doses)
Number of subjects: 211
Study 23759268 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan
Number of subjects: 36
Study 23759268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21148531 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 506
Study 21148531 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 506
Study 19926006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (pacemaker information transmitted at 3-month intervals)
Number of subjects: 0
Study 19926006 — intervention group
Group type: COMPARATOR
Intervention: Control (transtelephonic monitoring with office visits)
Number of subjects: 0
Study 19926006 — intervention group
Group type: COMPARATOR
Intervention: Control (transtelephonic monitoring)
Number of subjects: 0
Study 19926006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 0
Study 16421658 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered format (SA)
Number of subjects: 225
Study 16421658 — intervention group
Group type: COMPARATOR
Intervention: Parent and adolescent group format (PAG)
Number of subjects: 225
Study 15474212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall Man letters
Number of subjects: 0
Study 15474212 — intervention group
Group type: COMPARATOR
Intervention: Standard drug names
Number of subjects: 0
Study 11298617 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 61
Study 11298617 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 61
Study 9247610 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin administered on a single-day schedule
Number of subjects: 11
Study 9247610 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin administered on a 5-day schedule
Number of subjects: 11
Study 9247610 — intervention group
Group type: EXPERIMENTAL
Intervention: Calvert's formula for dosing carboplatin
Number of subjects: 11
Study 8320627 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 5 mg/kg per day for 6 months
Number of subjects: 21
Study 8320627 — intervention group
Group type: COMPARATOR
Intervention: Untreated children (control group)
Number of subjects: 21
Study 2446758 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 21
Study 2446758 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 21
Study 2446758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29230686 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer educational program (1-day program with theoretical and practical sessions)
Number of subjects: 110
Study 29230686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study 28219367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered structured smoking cessation program (4 sessions at 2 to 4 week intervals)
Number of subjects: 314
Study 28219367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered structured smoking cessation program
Number of subjects: 314
Study 28219367 — intervention group
Group type: COMPARATOR
Intervention: Control group (unstructured brief smoking cessation counseling)
Number of subjects: 314
Study 25249429 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 3 ProSeal™ laryngeal mask airway (PLMA)
Number of subjects: 152
Study 25249429 — intervention group
Group type: COMPARATOR
Intervention: Size 4 ProSeal™ laryngeal mask airway (PLMA)
Number of subjects: 152
Study 24660233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study 24660233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21081776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg with dexamethasone 10 mg
Number of subjects: 104
Study 21081776 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg IV with dexamethasone 10 mg
Number of subjects: 104
Study 20071893 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nursing intervention program (home visits every two weeks for three months)
Number of subjects: 42
Study 20071893 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 42
Study 17376581 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA providing visual and audio instructions
Number of subjects: 101
Study 17376581 — intervention group
Group type: COMPARATOR
Intervention: Control group without the PDA
Number of subjects: 101
Study 15525294 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day for 24 months (total exposure up to 36 months)
Number of subjects: 0
Study 11336137 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation through red palm oil (RPO) for 10 months
Number of subjects: 755
Study 10086898 — intervention group
Group type: COMPARATOR
Intervention: L-thyroxine supplementation (placebo group)
Number of subjects: 50
Study 7843446 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (hyperprolactinemia) with PRL > 20 ng/mL
Number of subjects: 49
Study 7843446 — intervention group
Group type: COMPARATOR
Intervention: Group I (control) with PRL ≤ 20 ng/mL
Number of subjects: 49
Study 2520495 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 13
Study 2520495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 836010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Number of subjects: 0
Study 836010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Number of subjects: 0
Study 836010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Number of subjects: 0
Study 836010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular and oral administration of amoxicillin
Number of subjects: 0
Study 836010 — intervention group
Group type: EXPERIMENTAL
Intervention: Total absorption of amoxicillin (via urinary recovery and AUC)
Number of subjects: 0